To evaluate the contribution of integrin-mediated cell adhesion to T-ALL progression after tumor establishment, we administered an anti-ICAM-1 blocking antibody alone or in combination with an anti-VCAM-1 blocking antibody after LN3 leukemic burden reached 1–8% in the spleen (Fig. 4a). This evidence concerns the gene ICAM1 and acute lymphoblastic leukemia.